Market Size of Global Carboprost Tromethamine Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.90 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Carboprost Tromethamine Market Analysis
The carboprost tromethamine market is projected to register a CAGR of 3.9% during the forecast period (2022 - 2027).
With the increase in COVID-19, there has been an increase in other complications that arise along with the infection. According to the American College of Obstetricians and Gynecologists' COVID-19 FAQs for Obstetrician - Gynecologists, Obstetrics updated in July 2020, carboprost tromethamine is contraindicated in pregnant women with asthma or other respiratory problems because the drug is associated with the occurrence of bronchospasm. The article mentions that although there are no specific data regarding the infection of COVID-19 with the use of carboprost tromethamine, the indications of COVID-19, especially viral pneumonia, can be a concern. As COVID-19 increases the risk of thrombosis due to the hypercoagulable state of pregnancy, the use of carboprost tromethamine should be carefully consulted before administration. An article presented in the journal Anesthesia and Analgesia in March 2020 reported a case of bronchospasm during the treatment of postpartum hemorrhage with carboprost tromethamine. The patient tested positive for COVID-19, which may have affected the treatment of postpartum hemorrhage. With the declining number of COVID cases, the adverse effects of the virus on the treatment of postpartum hemorrhage are expected to decrease, thereby fuelling the market growth over the forecast period.
Postpartum hemorrhage is the leading cause of maternal death worldwide. According to the article in June 2020 on Maternal Morbidity and Mortality from the National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development department of the United States Department of Health and Human Services, hemorrhage (also known as bleeding) is one of the leading causes of maternal mortality and morbidity. The number of postpartum cases worldwide is also increasing. According to an article published by the Commonwealth Fund in December 2020, severe postpartum hemorrhage accounts for about 11.1% of maternal mortality in the United States.
Furthermore, an article published on Abortion by the World Health Organization(WHO) in November 2021 confirmed the increasing rate of atonic postpartum hemorrhage in Saudi Arabia. It also reported that around 73.0 million induced abortions would take place worldwide annually. World Health Organization has included comprehensive abortion care in the list of essential health services for 2020. The increasing cases of postpartum hemorrhage and the increase in the number of abortions require appropriate drugs for the treatment and prevention of maternal mortality. Therefore, such an increase is expected to fuel the growth of the carboprost tromethamine market over the forecast period.
Carboprost Tromethamine Industry Segmentation
As per the scope of this report, carboprost tromethamine is a prostaglandin indicated for the treatment of bleeding due to postpartum hemorrhage and for producing abortion by causing uterine contractions. The carboprost tromethamine market is segmented by Application (Postpartum Hemorrhage Treatment and Pregnancy Abortion), Distribution Channel (Hospital Pharmacies, Retail pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers values in (USD million) for the above segments.
| By Application | |
| Postpartum Hemorrhage Treatment | |
| Pregnancy Abortion |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Carboprost Tromethamine Market Size Summary
The carboprost tromethamine market is poised for growth, driven by its critical role in managing postpartum hemorrhage, a leading cause of maternal mortality. The increasing incidence of postpartum hemorrhage, particularly in regions with high birth rates like India and China, underscores the demand for effective treatments. The market is also influenced by the rising number of abortions globally, as highlighted by the World Health Organization's inclusion of comprehensive abortion care as an essential health service. The drug's efficacy in preventing and treating postpartum hemorrhage, especially after cesarean sections, has been supported by various studies, which further propels its market potential. Additionally, the declining impact of COVID-19 on treatment complications is expected to contribute positively to market growth.
In North America, particularly the United States, the carboprost tromethamine market is anticipated to experience significant expansion due to high birth rates and the associated cases of postpartum hemorrhage. The presence of key market players, ongoing research and development, and the drug's proven effectiveness in treating uterine atony are pivotal factors driving this growth. The competitive landscape is characterized by several major players, including Pfizer and Merck KGaA, who are actively involved in product launches and strategic partnerships. Regulatory approvals, such as those from the FDA, further bolster the market's prospects. Overall, the carboprost tromethamine market is expected to witness robust growth, supported by its critical therapeutic applications and favorable market dynamics.
Global Carboprost Tromethamine Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Postpartum Hemorrhage
-
1.2.2 Increasing Demand for Contraceptive Pills
-
-
1.3 Market Restraints
-
1.3.1 Side Effects Associated With the Administration of Carboprost Tromethamine
-
1.3.2 Lack of Awareness Among Rural Population
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
2.1 By Application
-
2.1.1 Postpartum Hemorrhage Treatment
-
2.1.2 Pregnancy Abortion
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Online Pharmacies
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Carboprost Tromethamine Market Size FAQs
What is the current Global Carboprost Tromethamine Market size?
The Global Carboprost Tromethamine Market is projected to register a CAGR of 3.9% during the forecast period (2024-2029)
Who are the key players in Global Carboprost Tromethamine Market?
Merck KGaA, Pfizer, Universal Biologicals, Woodward Pharma and ChemScene are the major companies operating in the Global Carboprost Tromethamine Market.
